 | CodeLink detects up to 60% more of lower expressed genes!
News from the MicroArray Quality Control (MAQC) projectAccording to the most recent publications from the MicroArray Quality Control project (MAQC), the CodeLink bioarray platform from GE Healthcare detects nearly 30% more genes, relative to the other microarray platforms in all total RNA samples assessed. Also for lower expressed genes, CodeLink detects as much as 60% more when compared to other commercial microarray platforms.
These higher levels of sensitivity for the CodeLink platform are confirmed by external RNA control experiments in which CodeLink was proven to detect transcripts with concentrations as low as 50 fM.
Microarrays are an important tool that will be used to enable early health, drug target discovery, toxigogenomics and related fields. As such, detection sensitivity of microarrays is a key performance attribute to support expansion of genomics into clinical applications.
GE Healthcare is very pleased with the outcome of this study that proves the utility of microarrays, but also where CodeLink is crowned as the industry-leading platform in detection sensitivity.
More about the MAQC methodology
The MicroArray Quality Control project (MAQC) is a 2-year collaborative effort led by the U.S. Food and Drug Administration (FDA) to assess the performance of available commercial microarray platforms for profiling of total RNA samples. It includes 137 participants from 51 academic, government, and commercial institutions. During this extensive study, more than 1,300 microarrays were processed on seven microarray platforms that were deployed at three independant test sites. There were five replicates assayed at each site commercially using available standard reference total RNA samples.
Read more about CodeLink performance evaluation through the MAQC project |
